Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

  • Richard J Weaver*
  • , Eric A Blomme
  • , Amy E Chadwick
  • , Ian M Copple
  • , Helga H J Gerets
  • , Christopher E Goldring
  • , Andre Guillouzo
  • , Philip G Hewitt
  • , Magnus Ingelman-Sundberg
  • , Klaus Gjervig Jensen
  • , Satu Juhila
  • , Ursula Klingmüller
  • , Gilles Labbe
  • , Michael J Liguori
  • , Cerys A Lovatt
  • , Paul Morgan
  • , Dean J Naisbitt
  • , Raymond H H Pieters
  • , Jan Snoeys
  • , Bob van de Water
  • Dominic P Williams, B Kevin Park
*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    Abstract

    Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial pathophysiological process that cannot yet be recapitulated in a single in vitro model. Current preclinical testing regimes for the detection of human DILI thus remain inadequate. A systematic and concerted research effort is required to address the deficiencies in current models and to present a defined approach towards the development of new or adapted model systems for DILI prediction. This Perspective defines the current status of available models and the mechanistic understanding of DILI, and proposes our vision of a roadmap for the development of predictive preclinical models of human DILI.

    Original languageEnglish
    Pages (from-to)131–148
    JournalNature Reviews. Drug Discovery
    Volume19
    Early online date20 Nov 2019
    DOIs
    Publication statusPublished - 2020

    Fingerprint

    Dive into the research topics of 'Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models'. Together they form a unique fingerprint.

    Cite this